Official Title
Expanded Access Program to Treat Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma With Daraxonrasib
Brief Summary

This Expanded Access Program (EAP) is intended to provide daraxonrasib to eligible adultpatients with previously treated metastatic pancreatic adenocarcinoma, who have nocomparable or satisfactory alternative therapy and are unable to participate in anongoing daraxonrasib clinical trial.

Detailed Description

This EAP has been established to provide access to daraxonrasib to patients with
previously treated metastatic pancreatic adenocarcinoma during the period before
potential commercial availability. Patients may be eligible if they have progressed on,
are intolerant of, or are no longer expected to benefit from available standard
therapies, and if they are not able to enroll in a clinical trial of daraxonrasib due to
ineligibility or lack of access. This EAP is intended to address an unmet medical need
and is not designed to support clinical development objectives.

Daraxonrasib is an investigational, orally administered, RAS(ON) inhibitor administered
as monotherapy. Daraxonrasib will be supplied by the Sponsor free of charge during the
duration of treatment under this program.

Available
Treatment IND/Protocol
PDAC
PDAC - Pancreatic Ductal Adenocarcinoma
Metastatic Pancreas Adenocarcinoma
Pancreatic Cancer
Pancreatic Cancer Metastatic
Pancreatic Adenocarcinoma Metastatic
Pancreatic Adenocarcinoma
Pancreatic Adenosquamous Carcinoma

Drug: daraxonrasib

Oral tablets administered once daily
Other Name: RMC-6236,RMC-0706236

Eligibility Criteria

Inclusion Criteria:

- At least 18 years old and has provided informed consent.

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

- Histologically or cytologically confirmed PDAC with metastatic disease.

- Evidence of active disease progression during or following the most recent line of
systemic therapy for PDAC, based on investigator assessment.

- At least one prior line of systemic therapy in the metastatic setting, which must
include either a fluoropyrimidine-based or gemcitabine-based regimen.

- Received and progressed, been intolerant to prior standard therapy, or no longer
expected to benefit from standard therapies.

- Adequate bone marrow, renal, hepatic, and coagulation functions.

- Ineligible for, or unable to enroll in, another clinical trial of daraxonrasib, if
available.

- Able to take oral medications

Exclusion Criteria:

- History of known central nervous system metastatic disease.

- Concurrent systemic anticancer therapy.

- Significant cardiovascular disease.

- Major GI conditions that may affect the ability to take or absorb daraxonrasib
(patients with prior Whipple procedure are eligible).

- Active uncontrolled systemic infection.

- Major surgery within 28 days before enrollment.

- Additional inclusion and exclusion criteria may apply.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Puerto Rico
United States
Locations

Southern Cancer Center
Daphne, Alabama, United States

Southern Cancer Center
Mobile, Alabama, United States

Alaska Oncology and Hematology
Anchorage, Alaska, United States

Mayo Clinic - Arizona
Phoenix, Arizona, United States

Honor Health
Scottsdale, Arizona, United States

University of Arizona Cancer Center
Tucson, Arizona, United States

Mercy Hospital Fort Smith
Fort Smith, Arkansas, United States

Genesis Cancer and Blood Institute
Hot Springs, Arkansas, United States

Care Oncology Center
Chula Vista, California, United States

City of Hope Cancer Center (California)
Duarte, California, United States

USC Norris Comprehensive Cancer Hospital
Los Angeles, California, United States

Cedars-Sinai Medical Center
Los Angeles, California, United States

UCLA Health Westlake Village
Los Angeles, California, United States

University of California
Los Angeles, California, United States

El Camino Health
Mountain View, California, United States

University of California - San Francisco
Oakland, California, United States

UCI Health
Orange, California, United States

Desert Care Network Comprehensive Cancer
Palm Springs, California, United States

The Kaiser Permanente Medical Group
Roseville, California, United States

Sutter Health
Sacramento, California, United States

Sutter Health
San Francisco, California, United States

CommonSpirit
San Luis Obispo, California, United States

Stanford University
Stanford, California, United States

NorthBay Health Heidi Y Campini Cancer Center
Vacaville, California, United States

UCSF John Muir Health
Walnut Creek, California, United States

Rocky Mountain Cancer Center
Aurora, Colorado, United States

AdventHealth Porter
Denver, Colorado, United States

CommonSpirit Oncology Mercy
Durango, Colorado, United States

Lynn Cancer Institute - Boca Raton Regional Hospital
Boca Raton, Florida, United States

Memorial Cancer Institute
Hollywood, Florida, United States

Mayo Clinic - Florida
Jacksonville, Florida, United States

Sylvester Comprehensive Cancer Center
Miami, Florida, United States

Baptist Hospital of Miami
Miami, Florida, United States

Mount Sinai Medical Center of Florida
Miami Beach, Florida, United States

Florida Cancer Specialists and Research Institute
Naples, Florida, United States

Moffitt Cancer Center
Tampa, Florida, United States

Piedmont Physicians Medical Oncology
Atlanta, Georgia, United States

Emory University Hospital
Atlanta, Georgia, United States

Northwest Georgia Oncology Centers
Marietta, Georgia, United States

The Queen's Medical Center
Honolulu, Hawaii, United States

St Luke's Cancer Institute
Boise, Idaho, United States

Illinois Cancer Specialist
Arlington Heights, Illinois, United States

University of Chicago Medical Center
Chicago, Illinois, United States

Advocate Health Care
Downers Grove, Illinois, United States

Endeavor Health Cancer Institute
Naperville, Illinois, United States

OSF Cancer Institute
Peoria, Illinois, United States

University of Iowa Cancer Services Quad Cities
Bettendorf, Iowa, United States

University of Iowa
Waukee, Iowa, United States

Advent Health Shawnee Mission
Merriam, Kansas, United States

University of Kansas Medical Center
Westwood, Kansas, United States

Cancer Center of Kansas
Wichita, Kansas, United States

Baptist Health Lexington
Lexington, Kentucky, United States

Norton Cancer Institute
Louisville, Kentucky, United States

LSU LCMC Health Cancer Center
New Orleans, Louisiana, United States

New England Cancer Specialists
Topsham, Maine, United States

Johns Hopkins
Baltimore, Maryland, United States

Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States

Dana Farber Cancer Institute
Boston, Massachusetts, United States

University of Michigan
Ann Arbor, Michigan, United States

Karmanos Cancer Institute (Barbara Ann Karmanos Cancer Hospital)
Detroit, Michigan, United States

Henry Ford Health
Detroit, Michigan, United States

Hematology Oncology Consultants
Royal Oak, Michigan, United States

USOR: Minnesota Oncology Hematology, PA
Edina, Minnesota, United States

Mayo Clinic Minnesota
Rochester, Minnesota, United States

Park Nicollet Specialty Center
Saint Louis Park, Minnesota, United States

Health Partners Oncology
Saint Paul, Minnesota, United States

Jackson Oncology Associates
Jackson, Mississippi, United States

Mercy Hospital Joplin
Joplin, Missouri, United States

Saint Luke's Hospital of Kansas City
Kansas City, Missouri, United States

Mid America Cancer Care
Kansas City, Missouri, United States

Oncology Hematology Associates
Springfield, Missouri, United States

Mercy Hospital St. Louis-South
St Louis, Missouri, United States

Washington University School of Medicine
St Louis, Missouri, United States

Nebraska Cancer Specialists
Omaha, Nebraska, United States

Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, United States

MD Anderson at Cooper
Camden, New Jersey, United States

Overlook Medical Center - Medical Diagnostic Associates - Atlantic Medical Group
Morristown, New Jersey, United States

Hirschfeld Oncology
Brooklyn, New York, United States

Northwell Health
Lake Success, New York, United States

Memorial Sloan Kettering Cancer Center
Long Island City, New York, United States

NYU Langone Health
New York, New York, United States

The Mount Sinai Hospital
New York, New York, United States

New York Cancer and Blood Specialists
New York, New York, United States

Montefiore Medical Center
The Bronx, New York, United States

Duke Cancer Institute
Durham, North Carolina, United States

Carolina BioOncology Institute
Huntersville, North Carolina, United States

Blood and Cancer Center
Canfield, Ohio, United States

UH Seidman Cancer Centre
Cleveland, Ohio, United States

Zangmeister Cancer Center
Columbus, Ohio, United States

Premier Health OH
Dayton, Ohio, United States

Premier Health OH
Middletown, Ohio, United States

Mercy Hospital Oklahoma City
Oklahoma City, Oklahoma, United States

Compass Oncology
Happy Valley, Oregon, United States

Oregon Oncology Specialists
Salem, Oregon, United States

Willamette Valley Cancer Institute
Springfield, Oregon, United States

Lehigh Valley Hospital
Allentown, Pennsylvania, United States

Allegheny Health Network Cancer Institute
Butler, Pennsylvania, United States

Hematology & Oncology Associates of NEPA
Dunmore, Pennsylvania, United States

Alliance Cancer Specialists
Media, Pennsylvania, United States

Allegheny Valley Hospital
Natrona Heights, Pennsylvania, United States

Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States

Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States

Guthrie Sayre
Sayre, Pennsylvania, United States

Monument Health Cancer Care Institute
Rapid City, South Dakota, United States

Avera Cancer Institute
Sioux Falls, South Dakota, United States

West Cancer Center
Germantown, Tennessee, United States

Sarah Cannon Cancer Institute
Nashville, Tennessee, United States

Tennessee Oncology
Nashville, Tennessee, United States

MD Anderson Cancer Center
Houston, Texas, United States

Methodist Richardson Cancer Center
Richardson, Texas, United States

Utah Cancer Specialists (UCS)
Salt Lake City, Utah, United States

University of Vermont Medical Center
Burlington, Vermont, United States

Virginia Oncology Associates
Hampton, Virginia, United States

Riverside Health
Newport News, Virginia, United States

Virginia Cancer Institute
Richmond, Virginia, United States

Kadlec Regional Medical Center
Kennewick, Washington, United States

Seattle Integrative Cancer Center
Renton, Washington, United States

Virginia Mason Medical Center
Seattle, Washington, United States

Swedish Cancer Institute Treatment Center
Seattle, Washington, United States

Providence St. Mary Medical Center
Walla Walla, Washington, United States

Aurora Medical Center
Grafton, Wisconsin, United States

Marshfield Medical Center
Marshfield, Wisconsin, United States

Medical College of Wisconsin
Milwaukee, Wisconsin, United States

UW Health Cancer Center at ProHealth Care
Waukesha, Wisconsin, United States

PanOncology Centre
San Juan, Puerto Rico

Contacts

Revolution Medicines Study Director
1-844-2-REVMED
medinfo@revmed.com

Not Provided

Revolution Medicines, Inc.
NCT Number
Keywords
Expanded Access Program (EAP)
EAP
Daraxonrasib
RMC-6236
RMC-0706236
Metastatic pancreatic adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC)
RAS(ON) inhibitor
Unmet medical need
Pancreatic cancer
RAS
KRAS
Pancreatic Cancer Metastatic
Pancreatic Adenocarcinoma Metastatic
Pancreatic Adenosquamous Carcinoma
pancreatic adenocarcinoma
Compassionate Use
MeSH Terms
Pancreatic Neoplasms